1. Home
  2. CET vs UPB Comparison

CET vs UPB Comparison

Compare CET & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CET
  • UPB
  • Stock Information
  • Founded
  • CET 1929
  • UPB 2021
  • Country
  • CET United States
  • UPB United States
  • Employees
  • CET N/A
  • UPB N/A
  • Industry
  • CET Finance/Investors Services
  • UPB
  • Sector
  • CET Finance
  • UPB
  • Exchange
  • CET Nasdaq
  • UPB NYSE
  • Market Cap
  • CET 1.3B
  • UPB 1.3B
  • IPO Year
  • CET N/A
  • UPB 2024
  • Fundamental
  • Price
  • CET $46.84
  • UPB $18.19
  • Analyst Decision
  • CET
  • UPB Strong Buy
  • Analyst Count
  • CET 0
  • UPB 4
  • Target Price
  • CET N/A
  • UPB $56.50
  • AVG Volume (30 Days)
  • CET 31.2K
  • UPB 257.1K
  • Earning Date
  • CET 01-01-0001
  • UPB 11-07-2024
  • Dividend Yield
  • CET 4.95%
  • UPB N/A
  • EPS Growth
  • CET 64.57
  • UPB N/A
  • EPS
  • CET 10.32
  • UPB N/A
  • Revenue
  • CET $23,374,777.00
  • UPB $2,207,000.00
  • Revenue This Year
  • CET N/A
  • UPB N/A
  • Revenue Next Year
  • CET N/A
  • UPB N/A
  • P/E Ratio
  • CET $4.51
  • UPB N/A
  • Revenue Growth
  • CET 41.71
  • UPB 82.10
  • 52 Week Low
  • CET $36.07
  • UPB $17.09
  • 52 Week High
  • CET $49.51
  • UPB $29.46
  • Technical
  • Relative Strength Index (RSI)
  • CET 47.39
  • UPB N/A
  • Support Level
  • CET $46.02
  • UPB N/A
  • Resistance Level
  • CET $47.25
  • UPB N/A
  • Average True Range (ATR)
  • CET 0.65
  • UPB 0.00
  • MACD
  • CET -0.27
  • UPB 0.00
  • Stochastic Oscillator
  • CET 23.43
  • UPB 0.00

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About UPB UPSTREAM BIO INC

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.

Share on Social Networks: